New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise ComparisonGopila Gupta, Dennis Dong Hwan Kim, May Chiu et al.|Blood|2023Cited by 0
Retrospective Evaluation of <i>BCR::ABL</i> Kinase Domain Mutation Profiles and Treatment Outcomes in Patients with Chronic Myeloid Leukemia to Confirm Clinical Relevance of in Vitro Sensitivity-Based Treatment Switch: Real-World ExperienceMaría Agustina Perusini, Dennis Kim, Jaeyoon Kim et al.|Blood|2024Cited by 0
Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML PatientsMay Chiu, Dennis Dong Hwan Kim, Jenny Ho et al.|Blood|2024Cited by 0